Diabetes Breakthrough: Can Stem Cells Reverse Retinal Damage?
"New research explores how adipose stem cells and their paracrine factors offer hope for treating early diabetic retinopathy, potentially preventing vision loss."
Diabetic retinopathy (DR), a common complication of diabetes, threatens the vision of millions worldwide. In its early stages, DR is characterized by neurovascular defects that, if left unaddressed, can lead to severe vision impairment and blindness.
Current treatments primarily target the advanced stages of DR, such as diabetic macular edema (DME) and proliferative DR (PDR), often after significant and irreversible vision loss has already occurred. This creates a critical need for therapies that can intervene earlier in the disease process, halting or reversing its progression before it reaches these advanced stages.
Exciting new research is exploring the potential of adipose-derived stem cells (ASCs) and their paracrine factors to therapeutically rescue early-stage DR features. This article dives into a groundbreaking study that investigates how ASCs, particularly those positive for the pericyte marker CD140b, and their secreted factors can combat the neurovascular defects characteristic of early DR.
The Burden of Diabetic Retinopathy
Diabetic retinopathy is a common and complex microvascular complication of diabetes mellitus. Hyperglycemia and related metabolic abnormalities can drive advanced disease toward fibrosis, visual impairment, and blindness. It is also described as one of the leading causes of blindness among working-age adults, while the disease pathology can prevent the retina's endogenous stem cells from contributing to natural repair.
From Disease Models to Stem Cell Therapy
Research on diabetic retinopathy has used clinical postmortems, animal models, and cell models to investigate disease progression and prognosis. The review titled "Stem cells and diabetic retinopathy: From models to treatment" examines how these foundations informed treatment research and discusses future directions for stem cell therapy. A separate bibliographic account describes the field's progression from foundational research toward consideration of stem cell treatment for diabetic retinopathy.
Stem Cells to the Rescue: How ASCs Protect the Retina
The study, published in Stem Cell Research & Therapy, focused on using human ASCs to treat early DR in a mouse model (Ins2Akita). Researchers hypothesized that ASCs, known for their regenerative properties, could protect and restore the delicate neurovascular structures of the retina. These cells can be easily obtained, and are considered multi potent, with ability to treat a range of degenerative conditions.
- ASC Transplantation: Direct intravitreal injections of CD140b-positive ASCs into the eyes of the mice.
- Paracrine Factor Delivery: Intravitreal injections of conditioned media (ASC-CM) from cytokine-primed ASCs, essentially delivering the healing factors secreted by the cells.
Targeted Delivery and Cell-Derived Therapies
Recent work is exploring injectable hydrogels that combine with drugs or stem cells to target retinal layers, prolong therapeutic retention, and improve bioavailability for sustained diabetic retinopathy treatment. Studies of bone marrow mesenchymal stem cell-derived exosomes report suppression of the Wnt/β-catenin pathway, with reductions in oxidative stress, inflammation, and angiogenesis in the diabetic retina. In a separate preclinical study, a single intravenous injection of human umbilical-cord mesenchymal stem cells at week 16 after streptozotocin injection, but not at week 8, was associated with improved inner nuclear layer thickness.
Unresolved Identification and Translation Challenges
The study of adipose stem cells in the Ins2Akita mouse model notes that PDGFRβ, also called CD140b, is not a bona fide adipose stem cell marker, even though it is constitutively expressed in most adipose stem cells and increases with culture from 40% to 70%. This marker issue illustrates why cell characterization remains important when interpreting experimental results. More broadly, a review of stem cell therapy for diabetes describes the field as promising but still facing substantial challenges, particularly as induced pluripotent stem cell applications and other approaches continue to develop.
Evidence Is Not Yet Directly Comparable
The listed aesthetic stem cell records report outcomes such as brighter facial appearance, fewer wrinkles, improved skin texture, and changes in stamina or melasma two weeks after therapy. Those reports do not provide diabetic-retinopathy outcomes, so they cannot establish that aesthetic stem cell results translate to retinal repair. By contrast, Diabetes UK reports that human clinical trials examining stem cell treatments for diabetic retinopathy are underway, including an early safety trial of CD34+ stem-cell injections for eye conditions such as diabetic retinopathy.
A Promising Future for Stem Cell Therapies in Diabetic Retinopathy
This research paves the way for further investigation into stem cell-based therapies for DR. While challenges remain, including optimizing delivery methods and ensuring long-term safety and efficacy, the potential of ASCs and their paracrine factors to prevent vision loss in diabetes is a beacon of hope for millions at risk. As studies continue, we may be on the cusp of a new era in DR treatment, shifting from managing late-stage complications to proactively protecting and restoring retinal health.
Promise Tempered by Variable Evidence
The 2019 review describes diabetic retinopathy as a leading cause of blindness among working-age adults and states that disease pathology can prevent endogenous stem cells from participating in natural retinal repair. It also reports that stem cell therapeutics have shown variable efficacy in preclinical models because diabetic retinopathy is multifaceted. Taken together, the source supports viewing stem cell therapy as a research opportunity rather than an established way to reverse retinal damage.